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Abstract: Under-detection and -reporting in the private sector constitute a major barrier in Viet Nam’s
fight to end tuberculosis (TB). Effective private-sector engagement requires innovative approaches.
We established an intermediary agency that incentivized private providers in two districts of Ho Chi
Minh City to refer persons with presumptive TB and share data of unreported TB treatment from July
2017 to March 2019. We subsidized chest x-ray screening and Xpert MTB/RIF testing, and supported
test logistics, recording, and reporting. Among 393 participating private providers, 32.1% (126/393)
referred at least one symptomatic person, and 3.6% (14/393) reported TB patients treated in their
practice. In total, the study identified 1203 people with TB through private provider engagement.
Of these, 7.6% (91/1203) were referred for treatment in government facilities. The referrals led to
a post-intervention increase of +8.5% in All Forms TB notifications in the intervention districts.
The remaining 92.4% (1112/1203) of identified people with TB elected private-sector treatment and
were not notified to the NTP. Had this private TB treatment been included in official notifications,
the increase in All Forms TB notifications would have been +68.3%. Our evaluation showed that an
intermediary agency model can potentially engage private providers in Viet Nam to notify many people
with TB who are not being captured by the current system. This could have a substantial impact on
transparency into disease burden and contribute significantly to the progress towards ending TB.
Keywords: tuberculosis; private sector; intermediary agency; referral; notification; Viet Nam
1. Introduction
Tuberculosis (TB) is a curable disease, yet an estimated 10 million people develop active TB and
1.5 million people succumb to TB each year [1]. It remains the deadliest disease caused by a single
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infectious agent and a major source of avoidable deaths worldwide. Over the first 6 months of 2020,
an estimated 867,000 persons died of TB as a negative consequence of the Covid-19 pandemic [2].
Moreover, it is estimated that about one-quarter of the world’s population is infected with subclinical,
noninfectious TB [3].
Viet Nam has a well-organized National Tuberculosis Control Programme (NTP). TB treatment is
provided free of charge at all public sector sites and reported TB treatment outcomes are high. In 2014,
Viet Nam committed to reduce TB prevalence to 20 per 100,000 by 2030 [4]. However, following the
second national prevalence survey in 2018 [5], the country’s estimated TB incidence rate was revised
upward from 124 to 174 per 100,000, suggesting that just 57% of the estimated burden was captured by
the NTP’s official TB case notification statistics [6].
In 1986, the government initiated a package of reforms [7] that shifted Viet Nam’s centralized,
public healthcare sector towards neoliberalism and later to New Public Management, which resulted
in the rapid development of a private healthcare sector [8]. Fueled by the country’s strong economic
growth and rising population welfare, demand for private sector services due to greater convenience
and quality perceptions has similarly increased [9].
People often prefer to seek care with non-NTP facilities owing to their flexibility regarding
diagnostic procedures, drug regimens and treatment observation methods, more convenient operating
hours and locations, and lower administrative burden [10]. Studies have shown that pharmacies
and private clinics represent the initial point of health care seeking for 50−70% of people with TB in
Viet Nam [11–13]. Despite the existence of a mandatory notification law since 2007 [14], the implementation
of this policy has been suboptimal. As such, the private healthcare sector is a major driver of ‘missed
people with TB’ and loss to follow-up (LTFU) [15].
The Ministry of Health subsequently passed a law in 2013 (Circular 02/2013/TT-BYT) to enable
systematic inclusion of private providers and public institutions outside of the NTP via four public-private
mix (PPM) engagement models: (1) referral; (2) diagnosis; and referral; (3) directly observed treatment
(DOT) provider and (4) full-service TB care facility [16]. The law has resulted in roughly 10% of
TB case notifications at the national-level coming from PPM initiatives. Yet over 80% of these PPM
notifications originate from public institutions, such as general care, military, and police hospitals that
are not specialized in TB care and thereby are outside of the technical supervision of the NTP. This
implies that private providers contribute only 2% to annual notifications nationwide. Meanwhile,
it is estimated that about half of Viet Nam’s ‘missing cases’ are taking their TB treatment outside
of the NTP network [17]. More importantly, there is evidence that private sector TB care is often of
substandard quality. Patients may suffer diagnostic delays with no bacteriological confirmation and
receive inappropriate or inadequate treatment regimens. Poor adherence support has resulted in loss
to follow-up rates of up to 65% [18–21].
A key reason for the limited engagement of private providers is the restrictive nature of Circular
02/2013/TT-BYT. Providers that wish to retain their clientele are expected to participate as a full-service
TB facility and fulfill associated diagnostic and reporting requirements, while submitting to close
oversight and supervision by the NTP. Meanwhile, benefits of participation, such as capacity building,
free medicines, and eligibility for monetary stipends at government rates, may be insufficiently powered
or implemented [16]. This has proven untenable for many non-NTP providers apart from large public
tertiary care facilities. As a result, it is critical to develop and evaluate engagement schemes, which
take into account the economic interests of smaller private providers.
One such scheme is the Private Provider Interface Agency (PPIA) model that has subsequently
been scaled through the Joint Effort for Elimination of Tuberculosis (JEET) to 23 states of India [22,23].
This model employs intermediary agencies [15,24] that aim to offer a tangible value proposition with
bottom-line impact rather than appeal to altruistic motivations [25,26]. This value proposition includes
free or discounted access to nucleic acid amplification testing (NAAT) and medicines at pre-negotiated
price-points for providers and patients and, perhaps most importantly, the option for private providers
to retain their customers and thereby their livelihoods [27]. The implementation of PPIA’s showed
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promising results in multiple sites throughout India [28,29] and has been recognized as one avenue of
sustainably scaling private sector engagement for TB worldwide [30].
In 2017, Friends for International TB Relief piloted a private-sector engagement initiative called
Proper Care Private Sector (PCPS), modeled after the successful PPIA pilots from India [27]. This pilot
investigated the feasibility of building a portfolio of private providers and measured the outputs of
incentivizing and supporting referral and reporting of private TB treatment.
2. Materials and Methods
2.1. Study Setting
This pilot was conducted in two districts of Ho Chi Minh City (HCMC), Viet Nam—District 10
and Go Vap—between July 2017 and March 2019. The intervention area had a combined population of
1.2 million people and notified 1070 people with All Forms of TB in the 12 months preceding the study.
In each district, there is a District TB Unit (DTU) responsible for managing diagnosis, treatment and
notification of TB according to NTP guidelines and for coordinating patient management with primary
health facilities. There were no official private sector TB-reporting entities in the evaluation area before
this study’s implementation.
2.2. Private Provider Engagement
We obtained lists of licensed private healthcare providers from each intervention district’s
regulatory authority. These providers included pharmacies, single-doctor practices and multi-doctor
clinics. In collaboration with licensing, health, and TB authorities, through consensus we conducted a
mapping exercise to identify priority providers with a high likelihood of encountering people who had
pulmonary TB, while categorically excluding certain specialists, such as dermatologists, obstetricians,
and gynecologists. Through repeated in-person and telephonic engagement, we recruited eligible
providers. Interested providers were invited to capacity building events organized in collaboration
with the Pham Ngoc Thach provincial lung hospital (PNT). The scope of these training events included
new diagnostic tests for TB and specifically Xpert MTB/RIF (Xpert) and the newly recommended
MTB/RIF Ultra assay [31], standardized TB treatment regimens, and follow-up schedules according to
NTP guidelines. We complemented these formal training events with one-on-one provider detailing
activities [32] to elaborate on the study’s procedures, the provider’s role and responsibilities, and the
benefits of participation. Providers were eligible to participate through two principal strategies:
diagnostic referral and private TB treatment reporting (Figure 1).Trop. Med. Infect. Dis. 2020, 5, x FOR PEER REVIEW 4 of 14 
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2.3. Diagnostic Referral Strategy
In this strategy, participating providers verbally screened their customers for TB symptoms and
distributed referral vouchers to anyone reporting at least one TB symptom, i.e., (productive) cough
or hemoptysis, weight/appetite loss, fatigue, fever, night sweats, chest pain, dyspnea. Symptomatic
persons could use the voucher to access a chest X-ray (CXR) subsidy of VND 50,000 (USD 2.20 at
an exchange rate of VND 22,700 = USD 1) at one of the study’s 12 participating radiology sites.
As the cost per CXR charged by these radiology sites ranged from VND 80,000 (USD 3.52) to VND
120,000 (USD 5.29), the radiography site collected the balance payment from the health-seeking person.
In comparison, the price for one CXR at the District TB Unit was VND 49,000 (USD 2.16) at the start of
the study and was subsequently raised to VND 69,000 (USD 3.04). Patients who elected to take their
TB treatment with a private provider were charged a consultation fee of between VND 80,000 and
VND 150,000 (USD 6.61) in addition to drugs and other services. According to field staff estimates,
the approximate average cost per visit per person at private facilities was VND 200,000 (USD 8.81).
Persons assessed with parenchymal abnormalities on CXR by the X-ray technician and verified by
the attending radiologist at the radiography site provided a sputum sample for free follow-on testing
with the Xpert assay. At selected sites, health-seeking persons also underwent smear microscopy,
in which case these results were requested from the participating provider as well. Sputum was
collected at the radiography site or by the referring private provider. Study staff collected sputum
specimens for transport to a designated government Xpert laboratory in Go Vap district. People with
Xpert-positive results were encouraged to take treatment at their closest DTU, or at PNT if their Xpert
result showed rifampicin resistance. When an individual was diagnosed and treated for TB via this
strategy, the private provider making the initial referral received a VND 500,000 (USD 22.07) payment
or approximately 2.5x the estimated average cost per visit per person. If the person chose to take TB
treatment with a private provider, the treatment was recorded through the study’s second strategy.
2.4. Private TB Treatment Reporting Strategy
The second strategy focused on documenting private TB treatment practices. Once a month,
study staff collected TB treatment information from participating private providers. This information
included individuals diagnosed through the diagnostic referral strategy above that elected treatment
outside of the NTP. Providers were paid VND 500,000 (USD 22.07) for each complete patient report,
which included the patient’s name, age, sex, address, CXR results, sputum test results (Xpert, smear,
culture, other), type of TB (pulmonary, extra-pulmonary), treatment regimen, and initiation dates.
Treatment outcomes were not systematically assessed in this pilot study due to resource limitations
and data provided by providers were sparse as providers did not conduct post-treatment follow-up
with patients.
Despite the attempts to characterize these treatment reports in detail, they were not recognized by
the NTP for official notification for several reasons. The primary reason was that these providers were
not registered as official PPM model 4 participants in accordance to 02/2013/TT-BYT and therefore had
not undergone required capacity building and site assessment by the NTP.
2.5. Statistical Analyses
We tabulated descriptive statistics for private provider engagement and participation, the number
and proportion of referred people progressing through the study’s TB care cascade by intervention
district and the private TB treatment reported to our study. We calculated the ratio of bacteriologic
confirmation over the number of successful CXR referrals. Official TB notifications were collected
from the two intervention districts for three years prior to the study and during the study period to
analyze trends of official TB notifications before and during the pilot. Additional notifications and
percent change from baseline were calculated using a pre-/post-intervention comparison of official
notification data in the intervention districts. Due to barriers outlined above, the collected private TB
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treatment cases were not included in the official NTP notification statistics, so that a second additionality
model was constructed to assess the impact of including these privately treated individuals in official
TB statistics for the intervention districts. Statistical analyses were performed on Stata version 13
(StataCorp, College Station, TX, USA).
2.6. Ethical Considerations
The Institutional Review Boards of Pham Ngoc Thach Hospital (155/NCKH-PNT) and the Hanoi
School of Public Health (324/2019/YTCC-HD3) granted scientific and ethical approval for this study.
The Ho Chi Minh City Provincial People’s Committee approved the implementation of the intervention
(4699/QD-UBND). Participating private providers granted permission to use data for the analyses based
on the terms and conditions of their practice. All personally identifying information was removed
prior to analysis.
3. Results
3.1. Private Provider Engagement and Participation
The study enumerated 1107 licensed private providers in the two intervention districts (Table 1).
Of these, 67.0% (742/1107) were targeted for recruitment based on the initial mapping exercise and
53.0% (393/742) of those targeted agreed to participate. Among participants, at least one staff member
of 48.6% of centers (191/393) attended a capacity building event. By the end of the study, we recorded
at least one referral for CXR from 32.1% (126/393).
Table 1. Summary of provider recruitment and participation referral yields by district (2017-Q3 to 2019-Q1).
Go Vap District 10 Total
All licensed private providers 626 481 1107
# deemed eligible for recruitment 469 (74.9%) 273 (56.8%) 742 (67.0%)
# who signed a participation agreement 139 (22.2%) 254 (52.8%) 393 (35.5%)
# trained by provincial lung hospital 119 (19.0%) 72 (15.0%) 191 (17.3%)
# with at least one referral 105 (16.8%) 21 (4.4%) 126 (11.4%)
# reporting private TB treatment 5 (0.8%) 9 (1.9%) 14 (1.3%)
Of the 126 private providers with at least one successful CXR referral (Table 2), 58.7% were
multi-doctor clinics and 25.4% were single-doctor practices. These two provider types accounted for
70.0% and 18.9% of referrals, respectively. The remaining referrals were from pharmacies, hospitals or
could not be traced to the source. The bacteriologic positivity rate among successful CXR referrals was
highest among single pulmonologist practices at 58.6%, followed by multi-doctor clinics at 21.9% and
single-doctor practices with no specialty focus at 11.2%. Eighty-two point two percent of the people
diagnosed with TB via the diagnostic referral strategy were referred by just ten private providers
constituting 7.9% (10/126) of those making at least one successful CXR referral and 2.5% (10/393) of
those signing participation agreements.
The study received TB diagnosis and treatment data from 3.6% (14/393) of participating private
providers. These consisted of 71.4% (10/14) single-doctor practices and 28.6% (4/14) multi-doctor clinics.
The top five providers supplying TB diagnosis and treatment data reported 81.7% (907/1112) of patients
on private TB treatment.
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Table 2. Summary of chest X-ray (CXR) referrals and Bac(+) TB detection by type of private provider
(2017-Q3 to 2019-Q1).
Providers with Signed
Participation Agreement
Providers with 1+
Successful CXR Referral
Successful
CXR Referrals
Bac(+) TB
Detection
Single doctor clinics 62 (15.8%) 32 (25.4%) 943 (18.9%) 118 (69.8%)
-Pulmonologists 17 (4.3%) 17 (13.5%) 144 (2.9%) 99 (58.6%)
-General practitioners 45 (11.5%) 15 (11.9%) 799 (16.0%) 19 (11.2%)
Multiple doctor clinics 111 (28.2%) 74 (58.7%) 3489 (70.0%) 37 (21.9%)
-Pulmonology specialists 3 (0.8%) 3 (2.4%) 48 (1.0%) 0 (0%)
-Other specialists 108 (27.5%) 71 (56.3%) 3441 (69.0%) 37 (21.9%)
Hospitals 2 (0.5%) 2 (1.6%) 4 (0.1%) 4 (2.4%)
Pharmacies 218 (55.5%) 18 (14.3%) 86 (1.7%) 5 (3.0%)
Community referrals 1 N/A N/A 17 (0.3%) 5 (3.0%)
Undefined provider type N/A N/A 445 (8.9%) 0 (0%)
Total 393 (100%) 126 (100%) 4984 (100%) 169 (100%)
1 Indicates referrals from a separate community-based ACF initiative that accessed a private sector radiology site for
CXR screening.
3.2. Detection and Reporting Yield
The study identified 1203 people with TB of whom 7.6% (91/1203) were referred and linked to
care with the NTP (Figure 2), while 92.4% (1112/1203) consisted of private TB treatment reports and
remained un-notified (Table 3). All 91 TB patients linked to care with the NTP were bacteriologically
confirmed. Among persons treated in the private sector, the proportion with bacteriologic confirmation
was 30.5% (339/1112). Together, the total proportion of TB patients with bacteriologic confirmation was
35.7% (430/1203). Overall, 1.2% (15/1203) were people with Multi-drug resistant TB (MDR-TB). Patients
diagnosed with rifampicin resistance were largely referred by private providers to NTP facilities.
Particularly, diagnostic referrals generated 93.3% (14/15) of persons detected with rifampicin resistance
(Figure 2). Meanwhile, private TB treatment reports included one MDR-TB case (Table 3). In addition
to persons treated for active TB, four persons were treated for latent TB infection by private providers.
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Table 3. Summary characteristics of reported private TB treatment by district.
Go Vap District 10 Total
Private providers reporting private TB treatment 5 9 14
Private TB treatment reported 507 605 1112
Average number of privately treated TB patients
reported per provider per quarter (range) 14.5 (0–54) 9.6 (0–59) 11.3 (0–59)
Provider type
Single-doctor practice 263 (51.9%) 389 (64.3%) 652 (58.6%)
Multi-doctor clinic 244 (48.1%) 216 (35.7%) 460 (41.4%)
Diagnosis
Bacteriologically-confirmed 172 (33.9%) 167 (27.6%) 339 (30.5%)
Clinically diagnosed 335 (66.1%) 438 (72.4%) 773 (69.5%)
Type of TB
Pulmonary drug susceptible TB 372 (73.4%) 471 (77.9%) 843 (75.7%)
Extra-pulmonary drug susceptible TB 110 (21.7%) 133 (22.0%) 243 (21.9%)
Pulmonary Multi-drug resistant TB 0 (0.0%) 1 (0.2%) 1 (0.1%)
Not reported 25 (4.9%) 0 (0.0%) 25 (2.2%)
Reported residency
Living in Go Vap or District 10 241 (47.5%) 81 (13.4%) 322 (29.0%)
Living in another district of HCMC 167 (32.9%) 290 (47.9%) 457 (41.1%)
Living outside of HCMC 99 (19.5%) 220 (36.4%) 319 (28.7%)
Not reported 0 (0.0%) 14 (2.3%) 14 (1.3%)
Treatment regimen
Standard first-line regimen 261 (51.5%) 498 (82.3%) 759 (68.3%)
Modified first-line regimen/no duration 244 (48.1%) 63 (10.4%) 307 (27.6%)
Streptomycin-containing regimen 0 (0.0%) 33 (5.5%) 33 (3.0%)
Levofloxacin-containing regimen 1 2 (0.4%) 10 (1.6%) 12 (1.1%)
None reported 0 (0.0%) 1 (0.2%) 1 (0.1%)
1 Includes second-line regimen.
The results of the study’s diagnostic referral strategy are in Figure 2. The 12 radiology centers
recorded 4984 CXR results, of which 817 were abnormal (16.4% of those with CXR results). Sputum
specimens were collected from 65.4% (534/817) of these individuals and tested on the Xpert assay with
a positivity of 25.8% (138/534) including 14 individuals with rifampicin-resistant TB (14/138 = 10.1%).
An additional 528 smear microscopy tests were conducted for individuals who did not get a CXR or
presented no radiographic abnormalities suggestive of TB but still reported TB symptoms, resulting in
the detection of 31 (31/528 = 5.9%) people with smear-positive TB. Of the total 169 people diagnosed
with bacteriologically-confirmed TB, 95.9% (162/169) were linked to care, corresponding to a ratio of
3.2% among successfully referred persons with a CXR screen. Among patients linked to care, 56.2%
(91/162) were initiated on treatment at a NTP facility, while 43.8% (71/162) elected to take treatment with
the initially referring private provider. These patients are included in the private TB treatment reports.
The characteristics of the privately-treated, un-notified 1112 individuals are in Table 3. Of these,
30.5% (339/1112) had either a positive smear microscopy, Xpert, and/or culture result. Just 29.0%
(322/1112) of those taking private TB treatment lived inside the study’s intervention area, with another
41.1% (455/1112) living in one of HCMC’s other 22 districts. About 28.7% (319/1112) of privately
treated persons were registered residents of other provinces, while the remaining 1.3% (14/1112) of
people had no documented address. Overall, 68.3% (759/1112) of people privately treated for TB
were prescribed a standard first-line regimen as per NTP guidelines, while the records for another
27.6% (307/1112) of people showed the correct drugs but were modified from the standard regimen
or missing information on duration. Three percent (33/1112) of treatments included streptomycin,
and 1.1% (12/1112) included levofloxacin.
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3.3. Notification Impact
Table 4 and Figure 3 summarize changes in the NTP’s TB case notifications in the study’s intervention
area and present the modeled impact of including private TB treatment on official notification statistics.
Bacteriologically-confirmed and All Forms TB notifications increased by +17.0% (+177 TB cases) and
+8.5% (+158 TB cases), respectively, over six quarters of implementation. If private TB treatment had
been eligible for inclusion in the official notification statistics, bacteriologically-confirmed and All
Forms of TB notifications would have increased by +49.7% (+516 TB cases) and +68.3% (+1270 TB
cases), respectively.
Table 4. Changes in public-sector TB case notification and private TB treatment by district and type of TB.
Bac(+) TB All Forms TB
Go Vap
Baseline period public-sector TB notifications 703 1315
Intervention period public-sector TB notifications 885 1493
Additional public-sector TB notifications +182 (+25.9%) +178 (+13.5%)
Private TB treatment reported during the intervention period +172 (+24.5%) 507 (+38.6%)
Theoretical additional TB notifications (public & private) +354 (+50.4%) +685 (+52.1%)
District 10
Baseline period public-sector TB notifications 336 544
Intervention period public-sector TB notifications 331 524
Additional public-sector TB notifications −5 (−1.5%) −20 (−3.7%)
Private TB treatment reported during the intervention period +167 (+49.7%) +605 (+111.2%)
Theoretical additional TB notifications (public & private) +162 (+48.2%) +585 (+107.5%)
Both Intervention Districts
Baseline period public-sector TB notifications 1039 1859
Intervention period public-sector TB notifications 1216 2017
Additional public-sector TB notifications +177 (+17.0%) +158 (+8.5%)
Private TB treatment reported during the intervention period +339 (+32.6%) +1112 (+59.8%)
Theoretical additional TB notifications (public & private) +516 (+49.7%) +1270 (+68.3%)
Baseline period = (2016-Q3 to 2017-Q2)*2 + 2017-Q3. Intervention period = 2017-Q3 to 2019-Q1.
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4. Discussion
Our pilot study showed that the PPIA model was effective in engaging a large number of private
providers in the Vietnamese urban setting to contribute to TB care and prevention efforts. We found
a substantial number of persons treated for TB in the private sector of HCMC, the vast majority of
whom were not known to the NTP. This indicates that creating enabling mechanisms, as well as further
scale-up and evaluation of private TB treatment reporting approaches, should be a critical component
of the TB response in Viet Nam’s urban areas.
Numerous studies have shown that effective engagement of private providers to screen for TB and
refer presumptive cases for diagnostic testing can be an efficient way to close the detection gap [33–35].
This was corroborated by the results of our study and particularly by the increase in All Forms TB
notifications compared to the baseline period. Moreover, this share of private provider contribution to
notifications (+8.5%) was over five times Viet Nam’s 2017 national average private sector contribution
rate (1727/105,733 = 1.6%) [36]. Lastly, and perhaps most telling, un-notified private TB treatment
reports corresponded to about 70% of the officially notified patient load in these two districts managed
by the NTP. Even though these districts are not representative of the average district in Viet Nam, they
present a compelling argument to expand novel private provider engagement models in the country’s
urban areas.
Meanwhile, the efficiency of this approach was evidenced by the high ratio of positively detected
cases among those successfully referred. This high ratio suggests a pre-screening step performed by
these healthcare professionals or self-selection by patients. The high ratio consequently implies the
risk of false-negative assessments and missed opportunities to engage persons with TB. Therefore,
more advocacy for providers and the general population to raise top-of-mind awareness about TB
is warranted.
As observed on our study and documented by PPM projects in other settings, a referral strategy in
isolation remains limited in both novelty and impact [37]. A more comprehensive engagement strategy
is required to identify TB patients accessing treatment via the private sector. Including the reported
private TB treatments into the NTP’s routine surveillance would have represented a substantial increase
in case notifications in the two study districts. However, since these providers did not complete the
NTP’s registration process as an accredited PPM partner, the private TB treatment records were not
recognized as official notifications. The registration process is arduous and accompanied by external
inspections and laborious reporting requirements, which can inhibit PPM participation for TB in
Viet Nam [16]. This suggests the need for bold policies that promote private provider participation.
This need is well-understood and has shown substantial impact in other settings once addressed [38,39].
Notification gains represent only the initial milestone. While all people with TB detected and
notified through the referral strategy were bacteriologically confirmed, we observed low levels of
bacteriologic confirmation among private-sector TB treatments, as only one-third was substantiated
by a positive sputum test. We further observed that clinical diagnoses and follow-up testing for
bacteriologically-confirmed patients oftentimes did not follow national treatment guidelines. As this
study focused on case detection, treatment outcomes were optional to report and sparse when collected.
Private providers did not employ a systematic follow-up process but also did not permit the study
to directly engage their customers for household contact investigations due to fears of reputational
damages from breaching patient confidentiality. This has also been observed in other settings [35]
and represents a crucial opportunity to improve quality of private-sector TB care. This is particularly
the case in light of the low attendance rate on the capacity building sessions offered by the study,
as they were not mandatory for study participation. Consequently, while the goal of policy reform
should be to remove unnecessary bureaucratic barriers to promote private provider participation, this
reform should be designed with the long-term goal of improving quality of care among all stakeholders
in mind.
Meanwhile, access to Xpert testing constituted a unique selling proposition of the PPIA to these
providers, which they could pass on to their clientele. This study was the first to enable commercial
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access to Xpert testing for non-PPM providers in Viet Nam, so that the consistent message across size
and geography of providers was that the ability to offer NAAT to their clients was a critical catalyst
for participation. While this dynamic may be a temporary effect until market access is established
through registration and formalization of a commercial distribution channel, intermediary agencies
in other settings should leverage these dynamics to build the private provider network. Increased
acceptance of Xpert testing has also been observed to result in a reduction of clinical diagnosis [40],
so that increasing private-sector Xpert uptake could substantially reduce the rate of over-diagnosis
and contribute to improved individual and public health outcomes. Efforts to optimize NAAT access
have proven effective in several settings through the Initiative for Promoting Affordable, Quality TB
tests [24,38,41].
An important lesson across both strategies was the need to sufficiently power monetary and
non-monetary incentives. Evidence suggests that referral and notification incentives can represent a
welcome income generation opportunity [42,43]. However, determining the appropriate threshold at
which the individual cost-benefit analysis turns favorable is critical. The level of USD 22.07 proved
sufficient to elicit private TB treatment reports among some, but it is safe to say that the 14 reporting
providers in our study did not constitute the entire spectrum of private TB treatment. For example,
risk-averse providers and those with a small caseload may have found the incentive to be insufficient to
offset the risk exposure and expected value of penalties of un-notified TB treatment. These incentives
may have also created inefficiencies whereby pulmonologists referred persons with TB through our
study that would also have been referred in our absence as this level of incentive was high compared
to traditionally paid amounts in Viet Nam [19,44,45]. Nevertheless, the costs of incentives paid by
our study to detect a person with TB were a fraction of estimated total costs of detecting a new case
through other systematic screening strategies [46] and warrant further optimization and evaluation.
A key success factor of the study was the broad coverage and participation of a diverse set of
private providers. This was evidenced by the fact that we received referrals from all types of providers
listed above and detected TB cases from most provider types. This effectiveness in generating leads
and detecting TB patients also suggests that we were able to target the right providers. One reason for
this was likely the detailed a priori landscaping and targeting, which allows implementers to have a
better sense of the options people have for care seeking and coverage of their interventions [22,47].
Our study faced several limitations. With respect to private-sector TB treatment, our study was
observational in nature, so that we did not attempt to change clinical practices. Similarly, we did not
systematically incentivize and collect treatment outcomes in this study, but we intend to do so in
future engagements. As such, provider willingness to alter behavior to meet international standards
of TB care and the extent to which previously mentioned aspiration of improving diagnostic and
treatment quality are feasible remain critical research questions to be answered on future studies.
Another limitation was that we were only able to verify private TB treatment through reviews and
abstractions of data, which were only available in patient records, as private providers did not permit
direct engagement of their customers. The study’s implementation area was limited, so that it is
necessary to test the model at a greater scale to strengthen the generalizability of these results. Lastly,
it also remains unclear, if this model or an adaptation thereof were appropriate in non-urban areas.
Nevertheless, this pilot study has elucidated the potential gains inherent in effective private sector
engagement to national and provincial stakeholders in Viet Nam. As has been noted elsewhere, future
work should focus on strengthening data systems, including the use of direct electronic data capture to
track referrals and loss to follow up between referral and CXR [38]. This work should also employ
mechanisms to verify that private TB treatment reports are genuine individuals who have not already
been reported elsewhere in the TB notification system. Finally, policy changes are required to facilitate
the scale-up of this approach.
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5. Conclusions
Private providers in HCMC are treating many people with TB who are not reported to the national
program, and it is critical to improve engagement approaches that arrive at a system, which allows
private providers to notify through the NTP. To achieve public health targets, this system will also
need to ensure the highest level of care adherent to national standards. Scaling effective private-sector
engagement efforts, such as this enhanced intermediary model, could have a strong impact on the
progress towards ending TB, and we recommend the NTP to scale up the model and through it to
build capacity for improvements in quality of TB diagnosis and care.
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